<DOC>
	<DOCNO>NCT00295646</DOCNO>
	<brief_summary>The primary objective , first , comparison tamoxifen anastrozole , second , comparison zoledronate add standard adjuvant therapy control accord disease-free survival ( DFS ) premenopausal patient non-metastatic breast cancer treat tamoxifen anastrozole . To assess whether zoledronate add standard adjuvant therapy decrease even prevent bone loss patient treat hormonal blockade combine antiestrogen aromatase inhibitor .</brief_summary>
	<brief_title>Tamoxifen Versus Anastrozole , Alone Combination With Zoledronic Acid</brief_title>
	<detailed_description>The trial conduct open multi-center phase III study , two-factorial study design accord GCP guideline . Patients randomly assign total 4 study group 1:1:1:1 assignment ratio . Several stratification criterion use order ensure balance distribution know risk factor . A total 1.803 patient enrol 4 arm . Patients either treated anastrozole ( 1mg daily 3 year ) tamoxifen ( 20mg daily 3 year ) , additionally receive either zoledronate ( 8mg q4 week 3 year ) zoledronate ( arm A : Nolvadex alone ; arm B : Nolvadex plus zoledronate ; arm C : Arimidex alone ; arm D : Arimidex plus zoledronate ) . Zoledronate administer i.v . injection dose 4 mg/month treatment period 3 year . Five BMD measurement perform subgroup patient ( 404 patient , enrol 3 centre ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Premenopausal , hormone receptorpositive patient Histologically verify ( minimally ) invasive breast cancer , local radical treatment 09 involved axillary lymph node ( â‰¥ 10 histologically examine node ) Tumor stage : pT1b3 , yT0 yT1a T1a , T4d , yT4 ; M1 Previous breast tumor irradiation Previous concurrent chemotherapy ( except preoperative chemotherapy ) Serum creatinine &gt; 1.5 x UNL creatinine clearance &lt; 60 ml/min</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>ABCSG</keyword>
	<keyword>12</keyword>
	<keyword>Phase 3</keyword>
	<keyword>breast cancer</keyword>
	<keyword>anastrozole</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>zoledronic acid</keyword>
	<keyword>premenopausal</keyword>
	<keyword>hormone receptor-positive</keyword>
	<keyword>Stage I</keyword>
	<keyword>Stage II</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>BMD</keyword>
	<keyword>bisphosphonate</keyword>
	<keyword>zoledronate</keyword>
</DOC>